Arbutus Biopharma Corporation
Financials
Valuation Metrics
Arbutus Biopharma Corporation's Market Cap is $833M. At end of 2025 it was $922M. Ranked #2514 of 3,116 in US market (top 81%), #1047 of 1,472 on NASDAQ (top 71%), #192 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 72%) by Market Cap.
Investment Metrics(as of 2026-10-30)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $833M | US#2,514/3,116 Sec#192/265 |
| Revenue | $182M | US#2,566/3,116 Sec#112/265 |
| Net Income | $153M | US#1,418/3,116 Sec#49/265 |
| Total Assets | $274M | US#2,923/3,116 Sec#217/265 |
| Net Assets | $259M | US#2,569/3,116 Sec#164/265 |
| Employees | 19 | US#2,755/3,116 Sec#219/265 |
| Value | ||
| P/E | 5.44x | US#68/3,116 Sec#5/265 |
| P/B | 3.22x | US#1,849/3,116 Sec#102/265 |
| P/S | 4.58x | US#2,226/3,116 Sec#76/265 |
| EV/EBITDA | 5.33x | US#209/3,116 Sec#8/265 |
| FCF Yield | -2.96% | US—/3,116 Sec—/265 |
| Profitability | ||
| ROE | 59.16% | US#92/3,116 Sec#7/265 |
| ROA | 55.85% | US#8/3,116 Sec#3/265 |
| Op. Margin | 81.03% | US#23/3,116 Sec#1/265 |
| Revenue Growth | 1080.69% | US#15/3,116 Sec#9/265 |
| Financial Health | ||
| Debt Ratio | 5.91% | US#50/3,116 Sec#22/265 |
| Total Debt | $4M | US#2,917/3,116 Sec#222/265 |
| FCF | $-25M | US#2,443/3,116 Sec#99/265 |
| Cash | $19M | US#2,866/3,116 Sec#256/265 |
| Current Ratio | 81.42x | US#39/3,116 Sec#2/265 |
| Net Debt/EBITDA | -0.10x | US#532/3,116 Sec#31/265 |
| Performance | ||
| 1Y Return | -12.91% | US#2,057/3,116 Sec#165/265 |
| 1M Return | -11.82% | US#2,498/3,116 Sec#185/265 |
| From 52W High | -22.66% | US#1,604/3,116 Sec#92/265 |
| 1Y MDD | -25.86% | US#1,005/3,116 Sec#45/265 |
| Trading | ||
| Volume | 1,995,537 shares | US#1,362/3,116 Sec#135/265 |
| Trading Value | $8M | US#2,632/3,116 Sec#214/265 |
| Per Share | ||
| EPS | $0.77 | US#1,746/3,116 Sec#53/265 |
| BPS | $1.31 | US#2,647/3,116 Sec#189/265 |
Company Info
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.